Assessment cycle 2023 Q1 — page 6
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low21 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low03 Nov 2023 -
Randomised crossover, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low15 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Kisspeptin-10 in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported…
Very low16 Nov 2023 -
Observational, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low04 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Dec 2023 -
Single-arm open-label, phase 2 study of Pramlintide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low17 Aug 2023 -
Observational, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low02 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low18 Mar 2024 -
Single-arm open-label, phase 3 study of Semaglutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low26 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low12 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low28 Sep 2023 -
Randomised crossover, phase 1 study of Semaglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Apr 2023 -
Randomised crossover, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low31 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low22 Mar 2024 -
Observational, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low09 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low11 Feb 2024 -
Observational, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low04 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low21 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 May 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 May 2023 -
Single-arm open-label, phase 3 study of Tirzepatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low12 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low30 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 May 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low17 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low06 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low13 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low11 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low30 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Apr 2023
page 6 of 13